Novozymes A/S (NVZMY) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Novozymes A/S (NVZMY) trades at $69.51 with AI Score 62/100 (Grade B+). Novozymes A/S (NVZMY) is a leading global biotechnology company specializing in industrial enzymes and microorganisms across various sectors. Market cap: $32.4B, Sector: Basic materials.
Price as of Aug 20, 2026 · Last analyzed: Jun 15, 2026NVZMY stock analysis for 2026: Analysts have set a consensus price target of $71.33 for Novozymes A/S, suggesting 2.6% upside from the current price of $69.51. The AI MoonshotScore is 62/100, indicating a bullish outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
NVZMY: 1/3 scored disciplines lean bullish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Novozymes A/S (NVZMY) Materials & Commodity Exposure
Novozymes A/S is a global biotechnology leader specializing in industrial enzymes and microorganisms, serving diverse sectors including food, agriculture, and household care, with a strong commitment to sustainability and innovation.
What Is the Investment Thesis for NVZMY?
Novozymes A/S presents a compelling investment thesis driven by its strong market position and diverse product offerings. With a market capitalization of $32.4B, the company boasts a profit margin of 14.2% and a gross margin of 55.9%, indicating efficient operations. The ongoing trend towards sustainable solutions in various industries, particularly in agriculture and bioenergy, positions Novozymes favorably for growth. The company's focus on innovation and development of new enzyme solutions is expected to drive revenue growth, particularly as the global demand for sustainable and efficient production processes increases. However, investors should remain cautious of potential risks, including fluctuations in raw material costs and competitive pressures from emerging biotechnology firms.
Based on FMP financials and quantitative analysis
NVZMY Key Highlights
Market capitalization of $32.4B, reflecting a strong market presence.
- Profit margin of 14.2%, indicating effective cost management.
- Gross margin of 55.9%, exceeding industry averages.
- Return on equity (ROE) of 5.4%, showcasing shareholder value generation.
- Debt-to-equity ratio (D/E) of 29.42, indicating a conservative capital structure.
Who Are NVZMY's Competitors?
NVZMY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| AMSYF ArcelorMittal S.A. | $66.45 | +0.00% | $50.1B | 44 |
| PTPIF PT. Chandra Asri Petrochemical Tbk | $0.53 | +0.00% | $45.5B | — |
| GVDNY Givaudan S.A. | $80.07 | +3.09% | $37.0B | 53 |
| AKZOY Akzo Nobel N.V. | $23.60 | +1.81% | $36.3B | 44 |
| SXYAY Sika AG | $22.81 | -1.38% | $36.6B | 47 |
| PPG PPG Industries, Inc. | $112.44 | -1.30% | $25.0B | 78 |
| SQM Sociedad Química y Minera de Chile S.A. produces and distributes specialty plant nutrients, iodine and its derivatives, lithium and its derivatives, potassium chloride and sulfate, industrial chemicals, and other products and services. The company | $75.38 | +1.22% | $21.5B | 53 |
| IFF International Flavors & Fragrances Inc. | $83.33 | +2.88% | $21.3B | 53 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are NVZMY's Key Strengths?
Established leader in the industrial enzymes market.
- Strong commitment to sustainability and innovation.
- Diverse product offerings across multiple sectors.
- Robust global distribution network.
What Are NVZMY's Weaknesses?
Limited presence in emerging markets compared to competitors.
- Dependency on specific raw materials which may face price volatility.
- No dividend yield, which may deter income-focused investors.
What Could Drive NVZMY Stock Higher?
Launch of new enzyme products targeting sustainable agriculture in Q3 2026.
- Expansion into emerging markets with a focus on bioenergy solutions.
- Continued investment in R&D to enhance product offerings and efficiency.
What Are the Key Risks for NVZMY?
Inconsistent delivery — missed Wall Street EPS estimates in 5 of the last 8 reported quarters.
- Rich valuation — a P/E of 43.4 runs well above the Basic Materials sector’s ~22x, leaving little room for a miss.
- Fluctuating raw material costs impacting profit margins.
- Competitive pressures from emerging biotechnology firms.
- Regulatory changes affecting operational capabilities in key markets.
What Are the Growth Opportunities for NVZMY?
- Sustainable Agriculture: The global market for sustainable agricultural solutions is projected to reach $30 billion by 2027. Novozymes' innovative products in crop cultivation and bioyield enhancement position the company to capture significant market share as farmers increasingly adopt sustainable practices.
- Bioenergy Expansion: The bioenergy market is expected to grow at a CAGR of 8% through 2030, driven by the need for renewable energy sources. Novozymes' enzyme solutions for biomass transformation and fermentation processes are critical for biofuel production, presenting a substantial growth opportunity.
- Novozymes' extensive portfolio in food processing aids, particularly in baking and dairy, positions the company to capitalize on this growing demand for efficiency and quality in food production.
- Novozymes' specialized formulations for laundry and dishwashing provide a competitive edge in this expanding market.
- Novozymes' offerings in specialized lipases and proteases for biocatalysis are well-positioned to benefit from the increasing demand for biopharmaceutical solutions.
What Are NVZMY's Competitive Advantages?
- Strong brand reputation as a leader in the industrial enzymes market.
- Extensive research and development capabilities driving innovation.
- Diverse product portfolio catering to multiple industries.
- Established global presence with a broad customer base.
What Does NVZMY Do?
Founded in 1925, Novozymes A/S is a global biotechnology firm headquartered in Bagsvaerd, Denmark, renowned for its expertise in developing and distributing industrial enzymes, microorganisms, and probiotics. With a workforce of approximately 10,582 employees, Novozymes operates across multiple regions, including Europe, the Middle East, Africa, North America, Latin America, and the Asia Pacific. The company’s extensive product range addresses various industries, such as Food and Beverages, where it supplies essential ingredients and processing aids for baking and dairy production. In Household Care, Novozymes delivers specialized formulations for laundry and dishwashing. The Agriculture sector benefits from its innovations in crop cultivation and animal health, while its Bioenergy and Industrial Processing division provides critical components for grain processing. Additionally, Novozymes enhances Textile, Pulp and Paper, and Leather Production processes through advanced enzymatic solutions. The company is also involved in Water and Waste Management, offering bioaugmentation strategies, and Pharmaceuticals, supplying vital enzymes for biocatalysis. Novozymes' commitment to sustainability and innovation has solidified its position as a leader in the industrial enzymes market, making it a key player in the global biotechnology landscape.
What Products and Services Does NVZMY Offer?
- Develop and distribute industrial enzymes for various applications.
- Provide microorganisms and probiotics for agricultural and health sectors.
- Offer specialized formulations for household cleaning products.
- Create solutions for bioenergy and industrial processing.
- Enhance food and beverage production with innovative processing aids.
- Deliver enzyme solutions for textile, pulp, and paper industries.
How Does NVZMY Make Money?
- Generate revenue through the sale of industrial enzymes and microorganisms.
- Provide customized solutions for various industry needs.
- Engage in research and development to innovate new products.
- Collaborate with partners to expand market reach and product applications.
What Industry Does NVZMY Operate In?
The specialty chemicals industry, particularly in biotechnology, is experiencing significant growth driven by increasing demand for sustainable solutions across various sectors. The global market for industrial enzymes is projected to expand as industries seek to enhance efficiency and reduce environmental impact. Novozymes A/S, as a leader in this space, benefits from its established reputation and innovative product offerings. The competitive landscape includes notable players such as ArcelorMittal S.A. (AMSYF), PT. Chandra Asri Petrochemical Tbk (PTPIF), Givaudan S.A. (GVDNY), Akzo Nobel N.V. (AKZOY), and Sika AG (SXYAY), each vying for market share in a rapidly evolving industry.
Who Are NVZMY's Key Customers?
- Food and beverage manufacturers seeking processing aids.
- Agricultural companies focused on sustainable crop solutions.
- Household care brands looking for effective cleaning formulations.
- Bioenergy producers requiring enzyme solutions for production.
- Textile and paper industries aiming to enhance processing efficiency.
Company Profile
Novozymes A/S operates in the Chemicals - Specialty industry within the Basic Materials sector. It is headquartered in Lyngby, DK. The company is led by CEO Ester Baiget. NVZMY has traded publicly since 2010.
Novozymes A/S Financial Trajectory
Novozymes A/S (NVZMY) reported $1.14B in revenue for Q1 2026, reflecting 14.2% growth compared to the prior quarter. The company recorded net income of $202.4M, with diluted EPS of $0.43. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Basic Materials. Across the four most recent quarters, NVZMY averaged $0.26 in diluted EPS.
How Novozymes A/S Is Valued
Novozymes A/S carries a market capitalization of $32.4B, placing it in the large-cap category. Relative to its peer group, NVZMY's quantitative score of 62/100 is above the peer average of 47/100.
Key Financial Metrics
Return on equity for Novozymes A/S stands at 5.5%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.6%, showing how much profit it generates from its asset base. NVZMY trades at a trailing price-to-earnings ratio of 43.41, above the Basic Materials sector average of ~22x. Its free cash flow yield is 3.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.67 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 2.3%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
Novozymes A/S's Piotroski F-Score is 5/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 22.86 places it in the safe zone, indicating low near-term bankruptcy risk.
Earnings Track Record
Novozymes A/S has missed Wall Street's EPS estimate in 5 of its last 8 reported quarters — a mixed record worth weighing. Reported results have landed about 16.4% below estimates on average.
Forward Outlook
Wall Street analysts project Novozymes A/S revenue of about $33.56B for fiscal 2026, with EPS near $15.52. The estimate reflects 8 contributing analysts.
NVZMY Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Novozymes' future growth, indicating that key stakeholders believe in the company's potential.
- Community sentiment has turned positive, with many discussions highlighting Novozymes' innovative product pipeline and sustainability initiatives.
- Market perception is shifting favorably as Novozymes continues to strengthen its position in the biotechnological sector, capitalizing on the green transition.
- Analysts are noting that Novozymes' strong partnerships with major corporations enhance its market reach and credibility, boosting investor confidence.
Bear Case
- Concerns over supply chain disruptions have surfaced, potentially impacting Novozymes' ability to meet customer demand in the near term.
- Some community members express skepticism about the company's ability to maintain growth amidst increasing competition in the biotechnology space.
- Recent fluctuations in commodity prices may affect Novozymes' cost structure, leading to uncertainty in profitability moving forward.
- Investor sentiment remains cautious due to broader market volatility, with some viewing Novozymes as vulnerable to economic downturns.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.14B | $202M | $0.43 |
| Q4 2025 | $997M | -$765M | $0.26 |
| Q3 2025 | $1.06B | $137M | $0.30 |
| Q2 2025 | $137M | $18M | $0.04 |
Based on FMP financials and quantitative analysis
NVZMY Latest News
-
FUL or NVZMY: Which Is the Better Value Stock Right Now?
zacks.com · Jul 22, 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· Mar 24, 2020
NVZMY Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for NVZMY.
Price Targets
Consensus target: $71.33
NVZMY MoonshotScore
What does this score mean?
The MoonshotScore rates NVZMY 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Ester Baiget
CEO
Ester Baiget has a distinguished career in the biotechnology sector, having held various leadership roles within Novozymes since joining the company. She holds a degree in Chemical Engineering and has extensive experience in managing large teams and driving innovation. Prior to becoming CEO, she served as the head of several key business units, contributing to the company's strategic direction and growth.
Track Record: Under Ester Baiget's leadership, Novozymes has focused on enhancing its product portfolio and expanding its global reach. She has been instrumental in driving sustainability initiatives and fostering a culture of innovation within the company, leading to significant advancements in enzyme technology.
Novozymes A/S ADR Information Unsponsored
An American Depositary Receipt (ADR) is a negotiable certificate representing shares in a foreign company, allowing U.S. investors to buy shares without dealing with foreign currencies. NVZMY operates as a Level I ADR, meaning it is traded over-the-counter and does not require SEC registration.
- Home Market Ticker: Bagsvaerd, DK
- ADR Level: 1
- ADR Ratio: 1:1
- Home Market Ticker: NVZM
NVZMY OTC Market Information
The OTC Other tier represents securities that are traded over-the-counter but do not meet the higher standards of the NYSE or NASDAQ. This tier includes companies that may have less liquidity and transparency compared to those listed on major exchanges.
- OTC Tier: OTC Other
- Limited liquidity may result in higher volatility and difficulty executing trades.
- Less stringent reporting requirements could lead to less transparency.
- Currency fluctuations may impact the value of investments.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market position.
- Monitor currency exchange rates impacting ADR value.
- Research regulatory changes affecting international operations.
- Evaluate management's track record and strategic direction.
- Established history since 1925 with a strong brand reputation.
- Membership in industry associations and compliance with regulations.
- Consistent innovation and product development in biotechnology.
Common Questions About NVZMY (Basic Materials)
What does the AI Score mean for NVZMY?
NVZMY holds an AI Score of 62/100 (Grade: B+). This is an educational research signal, not a buy or sell recommendation. Novozymes A/S (NVZMY) is a leading global biotechnology company specializing in industrial enzymes and microorganisms across various sectors. Founded in 1925 and headquartered in Bagsvaerd …
What does Novozymes A/S do?
Novozymes A/S is a global biotechnology company specializing in the development of industrial enzymes, microorganisms, and probiotics. The company serves various sectors, including food and beverages, agriculture, household care, and pharmaceuticals, providing innovative solutions that enhance efficiency and sustainability in production processes.
What do analysts say about NVZMY stock?
Analysts generally view NVZMY as a strong player in the biotechnology sector, noting its leadership in industrial enzymes and commitment to sustainability. Key valuation metrics include a profit margin of 14.2% and a gross margin of 55.9%, indicating operational efficiency. Growth considerations focus on the company's innovative product pipeline and expansion into emerging markets.
What are the main risks for NVZMY?
Novozymes A/S faces several risks, including fluctuating raw material costs that could impact profitability. Additionally, the company must navigate competitive pressures from emerging biotechnology firms that may offer alternative solutions. Regulatory changes in key markets could also pose challenges, affecting operational capabilities and market access.
What are the key factors to evaluate for NVZMY?
Novozymes A/S (NVZMY) holds an AI score of 62/100 (moderate). P/E: 43.4x vs the S&P 500's ~20-25x. Analysts target $71.33 (+3%). Not financial advice.
How frequently does NVZMY data refresh on this page?
NVZMY's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven NVZMY's recent stock price performance?
Novozymes A/S (NVZMY) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Established leader in the industrial enzymes market. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider NVZMY overvalued or undervalued right now?
Novozymes A/S (NVZMY) trades at 43.4x earnings. Analysts target $71.33 (+3%) — near fair value. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research NVZMY before investing?
Before investing in Novozymes A/S (NVZMY), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The information provided is based on the latest available data and may be subject to change.